Penumbra raises 2025 revenue guidance to $1.375B–$1.38B as CAVT and embolization drive growth (NYSE:PEN)
Penumbra(US:PEN) Seeking Alpha·2025-11-06 08:32To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...